TrialScientific reports2024

A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II).

Kenichi Suzuki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.